

DAFTAR PUSTAKA

1. Hellier WPL. Chronic Otitis Media. In: Watkinson JC, Clarke RW, eds. Scott-Brown's Otorhinolaryngology Head and Neck Surgery Volume 2. Eight Edit. New York: Taylor & Francis Group; 2018:155–163
2. Mahdiani S, Lasminingrum L, Anugrah D. Management evaluation of patients with chronic suppurative otitis media: A retrospective study. *Ann Med Surg.* 2021;67(38):1-5.
3. Dhingra P, Dhingra S. Cholesteatoma and Chronic Otitis Media. In: Disease of Ear, Nose, and Throat & Head and Neck Surgery. Seventh. New Delhi: Elsevier; 2018:73- 82.
4. A. Telian, Steven M, E. Eschmalbach, Cecelia M. Chronic Otitis Media. In: Ballenger's Otorhinolaryngology Head and Neck Surgery 16th edition. 2014. 261–93.
5. Castle JT. Cholesteatoma Pearls: Practical Points and Update. *Head Neck Pathol.* 2018;12(3):419–29.
6. Rutkowska J, Özgirgin N, Olszewska E. Cholesteatoma definition and classification: A literature review. *J Int Adv Otol.* 2019;13(2):266–71.
7. Leichtle A, Kurabi A, Leffers D, Därr M, Draf CS, Ryan AF, et al. Immunomodulation as a Protective Strategy in Chronic Otitis Media. *Front Cell Infect Microbiol.* 2022;12(3):1–16.
8. Draskog C, de Klerk N, Westerberg J, Mäki-Torkko E, Georén SK, Cardell LO. Extensive qPCR analysis reveals altered gene expression in middle ear mucosa from cholesteatoma patients. *PLoS One.* 2020;15(9):1–19.
9. Maslin SD and M. Physiology of Hearing. In: Watkinson JC, Clarke RW, eds. Scott-Brown's Otorhinolaryngology Head and Neck Surgery Volume 2. Eight. New York: Taylor & Francis Group; 2018:567-92.
10. Valentine P, Wright T. Anatomy and Embryology of the External and Middle Ear. In: Watkinson JC, Clarke RW, eds. Scott-Brown's Otorhinolaryngology Head and Neck Surgery Volume 2. Eight Edit. New York: Taylor & Francis Group; 2018:525- 43.
11. Mansour S, Magnan J, Haidar H, Nicolas K, Louryan S. Middle Ear Compartment. In: Comprehensive and Clinical Anatomy of the Middle Ear. New York: Springer; 2013:83- 102.
12. Wageih Felfela GM. Ear Anatomy. *Glob J Otolaryngol.* 2020;4(1):22–39.
13. Mittal R, Lisi C V., Gerring R, Mittal J, Mathee K, Narasimhan G, et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media. *J Med Microbiol.* 2019;64(10):1103– 16.
14. Dihn C, Goldenberg D, Goldstein B, Isaacson, JE, Lesnik G, Levi A. Otolgy and Neurootology. In: Goldenberg D, Goldstein B, editor. Handbook of Otolaryngology Head and Neck Surgery. second ed. New York: Thieme Publisher; 2018. hal. 127–45.

15. Yung M, Tono T, Olszewska E, Yamamoto Y, Sudhoff H, Sakagami M, et al. Eano/jos joint consensus statements on the Definitions, Classification and Staging of Middle Ear Cholesteatoma. *J Int Adv Otol*. 2019;13(1):1–8.
16. Edward Y, Decroli E, Ali H, Tjong DH. Expression of ccl27 in middle ear cholesteatoma. *Open Access Maced J Med Sci*. 2021;9(T3):240–3.
17. Jackler RK, Santa Maria PL, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. *Laryngoscope*. 2019;125(S4):1–14.
18. Kuo CL. Etiopathogenesis of acquired cholesteatoma: Prominent theories and recent advances in biomolecular research. *Laryngoscope*. 2020;125(1):234–40.
19. Kuo C-L. Recent Advances in Understanding the Pathogenesis of Acquired Cholesteatoma. *Recent Adv Otolaryngol Neck Surg*. 2020;(5):167–76
20. Hamed MA, Nakata S, Sayed RH, Ueda H, Badawy BS, Nishimura Y, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future prospectives. *Clin Exp Otorhinolaryngol*. 2019;9(4): 298–308.
21. Jackler RK, Santa Maria PL, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. *Laryngoscope*. 2019;125(S4):1–14.
22. Schürmann M, Greiner JFW, Volland-Thurn V, Oppel F, Kaltschmidt C, Sudhoff H, et al. Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS. *Cells*. 2020;9(1):1–17.
23. Jesic S, Jotic A, Tomanovic N, Zivkovic M, Kolakovic A, Stankovic A. Expression of Toll-Like Receptors 2, 4 and Nuclear Factor Kappa B in Mucosal Lesions of Human Otitis: Pattern and Relationship in a Clinical Immunohistochemical Study. *Ann Otol Rhinol Laryngol*. 2018;123(6):434–41.
24. Jung SY, Kim D, Park DC, Kim SS, Oh TI, Kang DW, et al. Toll-like receptors: Expression and roles in otitis media. *Int J Mol Sci*. 2021;22(15):1–17.
25. Lim HD, Robert Lane J, Canals M, Stone MJ. Systematic assessment of chemokine signaling at chemokine receptors ccr4, ccr7 and ccr10. *Int J Mol Sci*. 2021;22(8).
26. Xie S, Wang X, Ren J, Liu W. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. *Eur Arch Oto-Rhino-Laryngology*. 2018;274(5):2071–8.
27. Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. *BioMed Research International*; 2021;36(2):1-14

28. Bryant CE, Gay NJ, Heymans S, et al. Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. *Critical Reviews in Biochemistry and Molecular Biology* 2018; 50: 359–379.
29. Szczepański M, Szyfter W, Jenek R, et al. Toll-like receptors 2, 3 and 4 (TLR2, TLR-3 and TLR4) are expressed in the microenvironment of human acquired cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2020; 263: 603–7.
30. Westerberg J. Middle ear cholesteatoma. Surgical outcome and aspects of the innate immunity. Linköping: Linköping University, 2020
31. Hirai H, Kariya S, Okano M, et al. Expression of toll-like receptors in chronic otitis media and cholesteatoma. *Int J Pediatr Otorhinolaryngol* 2019; 77: 674–6.
32. Pusalkar AG. Cholesteatoma and Its Management. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2015; 67: 201–4.
33. Olszewska E, Wagner M, Bernal-Sprekelsen M, et al. Etiopathogenesis of cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2018; 261: 6–24.
34. Meyer TA, Jr CJS, Lambert PL. Cholesteatoma. In: Johnson JT, Rosen CA (eds) *Bailey's Head & Neck Surgery Otolaryngology Vol 2*. Philadelphia: Lippincott Williams & Wilkins, 2014, pp. 2433–43.
35. Si Y, Chen Y bin, Chen SJ, et al. TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction. *Sci Rep* 2020; 5: 1–13.
36. Mahfuzah, Djamin R, Sulaiman AB, et al. Analysis of Toll-Like Receptors-2 Expression in Patients with Chronic Suppurative Otitis Media with and Without Cholesteatoma. *journal of Xi'an Shiyou University* 2022; 65: 25–35.
37. Jotic A, Jesic S, Zivkovic M, et al. Polymorphisms in Toll-like receptors 2 and 4 genes and their expression in chronic suppurative otitis media. *Auris Nasus Larynx* 2018; 42: 431–7.
38. Lee HY, Park MS, Byun JY, et al. Expression of pattern recognition receptors in cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2019; 271: 245–53.
39. Granath A, Cardell LO, Uddman R, et al. Altered Toll- and Nod-like receptor expression in human middle ear mucosa from patients with chronic middle ear disease. *Journal of Infection* 2018; 63: 174–6.
40. Dahlan SM. Menggunakan Rumus Besar Sampel Secara Benar. In: *Besar Sampel dan Cara Pengambilan Sampel*. Jakarta: Salemba Medika, 2013: 35–72.
41. Sastroasmoro S, Ismael S. Perkiraan Besar Sampel. In: *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, 2008: 302–32
42. Mahajan T, Dass A, Gupta N, et al. Bacteriological Profile in Attico-antral type of Chronic Suppurative Otitis Media. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2019; 71: 1412–21.

43. Rosito LPS, da Silva MNL, Selaimen FA, et al. Characteristics of 419 patients with acquired middle ear cholesteatoma. *Braz J Otorhinolaryngol* 2017; 83: 126–31.
44. Keita A, Diallo I, Diallo MA, et al. Cholesteatoma of the middle ear: about 50 cases in Donka University Hospital. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2022; 8: 787–91.
45. Im GJ, do Han K, Park KH, et al. Rate of chronic otitis media operations and cholesteatoma surgeries in South Korea: a nationwide population-based study (2006–2018). *Sci Rep* 2020; 10: 1–10.
46. Handoko E, Indrasworo D, Harun Nur Salim A. Hubungan derajat kolesteatoma dengan keberhasilan operasi mastoidektomi radikal pada penderita otitis media supuratif kronis. *Oto Rhino Laryngologica Indonesiana* 2019; 49: 99–107.
47. Li J, Jufas N, Forer M, et al. Incidence and trends of middle ear cholesteatoma surgery and mastoidectomy in Australia—A national hospital morbidity database analysis. *Laryngoscope Investig Otolaryngol* 2022; 7: 210–8.
48. Natarajan K, Kurkure RS, et al. Management of advanced cholesteatoma: Madras ENT Research Foundation experience. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2020; 6: 1149–54.
49. Shwetha. Chronic otitis media with cholesteatoma: clinical presentation and surgical management. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2019; 4: 1212–19.
50. Mokbel Khalefa KM. Ten years incidence of intracranial complications of chronic suppurative otitis media. *Journal of Medical Research and Health Sciences* 2020; 3: 996–1001.
51. Maniu A, Harabagiu O, Schrepler MP, et al. Molecular biology of cholesteatoma. *Romanian Journal of Morphology and Embryology* 2018; 55: 7–13.
52. Ahmed Z, Khan TZ, Rahim DU. Otogenic complications of otitis media : experience at tertiary care hospital Received : Accepted : *Pak Surg.* 2019; 32: 49–53.
53. Lestari DY. *Tesis Perbedaan Kadar Lipopolisakarida Antara Otitis Media Supuratif Kronis Tipe Bahaya dengan Tipe Aman Fase Aktif*. Universitas Andalas, 2018.
54. Hidayat R. Pathophysiological to Clinical Aspects of Chronic Suppurative Otitis Media (CSOM): Narrative Literature Review. *Archives of The Medicine and Case Reports* 2022; 3: 246–55.
55. Hifni A, Rian Hasni, Fiona Widyasari, et al. Comparison of Germ Patterns and Antimicrobial Susceptibility in Chronic Suppurative Otitis Media with Cholesteatoma and without Cholesteatoma in Dr. Mohammad Hoesin Hospital. *Bioscientia Medicina: Journal of Biomedicine and Translational Research* 2021; 5: 647–56.
56. Novianti D. *Tesis Perbedaan Frekuensi Pembentukan Biofilm Bakteri Aerob pada Otitis Media Supuratif Kronis Tipe Aman Fase Aktif dengan Tipe Bahaya di RSUP Dr. M. Djamil Padang*. Universitas Andalas, 2016.
57. Rasheed N, Hussein N. Staphylococcus aureus: An overview of Discovery, Characteristics, Epidemiology, Virulence Factors and Antimicrobial

Sensitivity. European Journal of Molecular and Clinical Medicine
2021: 08:1-24

